XTalks

MAY 23, 2024

Eterovic brings much knowledge and experience to the table, having led the development of a new Oncology Diagnostic program at Eurofins Viracor that integrates the latest genomic profiling techniques. Eterovic highlights that the financial and logistical barriers to comprehensive genomic profiling are high but not impossible to overcome.

Genetics 115

Genetics Research Genome Genomics 115

The Pharma Data

OCTOBER 26, 2021

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. Cancer is a disease of the genome and treatment no longer depends solely on the tissue of origin.

Genome 52

Genome Genomics Research Medicine 52

Pharmaceutical Technology

OCTOBER 26, 2022

Gene therapy uses DNA to manipulate cells and correct defective genes, whereas cell therapy is the infusion or transplantation of cells into a patient. Early gene therapy methods were proposed in the 1970s, and the first approved gene therapy clinical research in the US began in 1990. The future of cell and gene therapies.

Gene Therapy 130

Gene Therapy Gene Marketing Manufacturing 130

XTalks

DECEMBER 20, 2023

This includes analyzing how drug combinations may impact individual patients or groups of patients before even entering a clinical trial. With a staggering 90 percent of drugs failing in clinical trials, AI has the potential to help improve these statistics.

Life Science 120

Life Science Gene Editing Development Clinical Trials 120

Cloudbyz

JUNE 26, 2023

Clinical Trial Design and Optimization: Generative AI can aid in the design and optimization of clinical trials. By simulating patient populations, generating synthetic trial data, and optimizing trial protocols, generative models can enhance the efficiency and effectiveness of clinical trials.

Clinical Research 97

Clinical Research Research Clinical Trials Clinical Trials 97

Bioengineer

JANUARY 16, 2024

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. months, 95% CI 1.3,

Genome 119

Genome Genomics Protein In-Vitro 119

XTalks

SEPTEMBER 9, 2021

It was found that the gene being delivered through the therapy had integrated into the genomes of six of the seven mice that were administered the highest dose. Although a rare event that occurs at very low frequency, AAV vectors can integrate into genomes through homologous recombination.

Gene Therapy 105

Gene Therapy Gene Genome Genomics 105

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Genuity Science focuses on population genomics as a tool to derive novel biological insights through partnerships with industry-leading pharmaceutical and biotech companies.

Research 98

Research Biobanking Drugs Genome 98

XTalks

JANUARY 21, 2025

In a clinical trial, participants demonstrated a 98% success rate after six months post implantation, with arteries widened successfully and no stent fractures observed. The Shield test provides a non-invasive approach to colorectal cancer screening by analyzing blood for key DNA changes linked to cancer. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

XTalks

MAY 10, 2022

Somatic variant classification and interpretation are the most time-consuming steps of tumor genomic profiling,” said the co-author of the study Marilyn M. Li, MD, Professor of Pathology and Laboratory Medicine, Director of Cancer Genomic Diagnostics. CancerVar provides a powerful tool that automates these two critical steps.

Bioinformatics 98

Bioinformatics Development Gene Genome 98

The Pharma Data

NOVEMBER 17, 2021

Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.

Scientist 52

Scientist RNA DNA Genetics 52

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

The Pharma Data

DECEMBER 14, 2020

Many drugs fail in clinical trials because of their low blood brain barrier permeability. engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. .

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

OCTOBER 19, 2020

With over 300 active clinical trials, Winship researchers are dedicated to taking new cancer treatments from bench to bedside. cancer centers selected as a Lead Academic Participating Site for the NCI’s National Clinical Trials Network (NCTN). Winship is one of 32 U.S.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

pharmaphorum

APRIL 20, 2022

In 2012, Jennifer Doudna and Emmanuelle Charpentier published a paper in Science where they outlined isolating the components of the CRISPR-Cas9 system and demonstrated how it could be used to cut specific sites in isolated DNA. The publication and their work eventually led to the pair being awarded the Nobel Prize in Chemistry in 2020.

Gene Editing 52

Gene Editing DNA Gene Genetics 52

Roots Analysis

AUGUST 15, 2023

Intracellular drug delivery system is used to deliver the genomic materials into specific cells to generate a therapeutic effect by correcting an existing abnormality or providing the cells with a new function. Use of non-viral vectors in clinical trials increased from 2004 to 2013 while that of viral vector saw significant decrease.

Drug Delivery 52

Drug Delivery Drugs Drug Delivery Systems Gene 52

Cloudbyz

JULY 31, 2024

Liquid biopsies, for example, allow non-invasive monitoring of cancer progression and response to treatment by analyzing circulating tumor DNA (ctDNA) in blood samples. Enhanced Clinical Trial Design: Rapid IVD development supports the design of more effective clinical trials for new therapies.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

The Pharma Data

APRIL 11, 2023

BAY 2927088 is a reversible small molecule inhibitor that is currently being evaluated in a first-in-human, Phase 1 clinical trial in non-small cell lung cancer (NSCLC) patients with mutations in epidermal growth factor receptors (EGFR & HER2) including exon20 insertions and point mutations.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. Liquid Biopsy Use in Oncology Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

OCTOBER 14, 2020

Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. The study led by Dr. Sergei Rudchenko, Ph.D.,

Vaccination 40

Vaccination Vaccine Development Medicine 40

Worldwide Clinical Trials

APRIL 7, 2025

Integrate Biomarkers Where Possible Biomarker integration is crucial in solid tumor clinical trials, though more research is needed before fully validated assays become the norm across solid tumor indications. Partnering with an experienced CRO and the right sites is essential to a successful solid tumor clinical trial.

Medicine 100

Medicine Research Clinical Trials Clinical Trials 100

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharmaceutical Technology

MARCH 29, 2023

The government is giving Touchlight £14 million for commercial scale manufacturing of its “doggybone DNA” vector at its Hampton, London base. This recent funding is one of many initiatives announced by the UK government to boost its life sciences sector after a downturn in clinical activity in recent years.

Life Science 276

Life Science Manufacturing Gene Therapy Medicine 276

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

pharmaphorum

SEPTEMBER 14, 2021

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – for hidden treasure. Most drug discovery programmes target the roughly 2% of the human genome which encodes for protein.

DNA 52

DNA Immune Response Genome Genomics 52

pharmaphorum

JANUARY 18, 2023

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. Fast forward to today and, while many large-scale genomics studies still lack the infrastructure and consent policies to enable recontact, this is starting to change. Giving participants something in return.

Genetic Disease 97

Genetic Disease Genetics Research Genome 97

pharmaphorum

SEPTEMBER 13, 2022

Although clinical trials proved that chemicals could be used to treat cancer, the results of the study remained a closely guarded military secret until 1946. 2012 – The 100,000 Genomics Project begins. Unlocking the secrets of the human genome has intrigued investigators for centuries.

Genome Project 98

Genome Project Genome Genomics DNA 98

XTalks

SEPTEMBER 2, 2021

It is known as the “guardian of the genome” given its central role in the DNA damage response. It senses damage to DNA and triggers protective mechanisms to try to repair it; if damage is extensive and beyond repair, it triggers death of the cell.

Protein 106

Protein DNA Antibody Genome 106

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 112

FDA Approval Gene Therapy Clinical Trials Gene 112

Delveinsight

DECEMBER 13, 2020

Even though clinical trial results were promising, adverse events and serious complications were observed. Unlike a typical virus, hepatitis B’s cccDNA permanently integrates itself into a healthy cell’s DNA. HBV DNA can be integrated into the host genome. Both drugs resulted in inhibition of HCV replication.

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

OCTOBER 14, 2020

The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients. The trial plans to evaluate safety, tolerability, cytokine profile and efficacy parameters.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

XTalks

DECEMBER 4, 2023

In a statement outlining its investigation, the FDA said it received reports of the T-cell malignancies from clinical trials and post-marketing safety monitoring. The vectors can potentially cause cancer by inserting genetic material into a patient’s genome, particularly near cancer-related DNA sequences or suppressors​​​​.

Gene Therapy 69

Gene Therapy Gene Clinical Trials Clinical Trials 69

The Pharma Data

SEPTEMBER 2, 2021

There are currently no TROP2-directed medicines approved for NSCLC, a setting where Dato-DXd has shown promising results in Phase I trials. Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies. DNA damage response. 8 September 2021. Antibody drug conjugates. Borghaei, H.

Trials 52

Trials Medicine Antibody Clinical Trials 52

pharmaphorum

DECEMBER 20, 2022

Through the use of genomic, proteomic, epigenetic, immunopeptidomic, and microscopy technologies, scientists are better able to examine cancer cells, molecules, and ecosystems at unprecedented resolution. A fresh approach.

Scientist 98

Scientist Research Genetics Drugs 98

XTalks

MAY 12, 2022

Register for this free webinar to learn what is currently known about the causes and consequences of pain catastrophizing with particular emphasis on the importance of assessing pain catastrophizing in clinical trials of treatments for persistent pain conditions. How Does Hologic’s Aptima CMV Test Work?

In-Vitro 52

In-Vitro DNA Development Genome 52

The Pharma Data

OCTOBER 19, 2020

Lipid nanoparticles are the most clinically advanced gene delivery system, overcoming nucleic acids delivery inefficiencies. . hATTR is an inherited DNA mutation of the TTR gene. Becky is now in Boston, enrolled in a clinical trial with monthly injections hoping to reverse her mutated proteins.

Gene 52

Gene Protein Trials DNA 52